A detailed history of Benjamin Edwards Inc transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Benjamin Edwards Inc holds 16,315 shares of BEAM stock, worth $412,606. This represents 0.01% of its overall portfolio holdings.

Number of Shares
16,315
Previous 147 10998.64%
Holding current value
$412,606
Previous $3,000 13200.0%
% of portfolio
0.01%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$22.57 - $33.14 $364,911 - $535,807
16,168 Added 10998.64%
16,315 $399,000
Q2 2024

Aug 12, 2024

SELL
$21.22 - $32.66 $1,931 - $2,972
-91 Reduced 38.24%
147 $3,000
Q1 2024

Apr 29, 2024

BUY
$23.46 - $45.07 $164 - $315
7 Added 3.03%
238 $8,000
Q4 2023

Feb 06, 2024

BUY
$17.69 - $30.76 $247 - $430
14 Added 6.45%
231 $6,000
Q3 2023

Nov 13, 2023

BUY
$23.01 - $32.46 $1,288 - $1,817
56 Added 34.78%
217 $5,000
Q2 2023

Aug 15, 2023

BUY
$29.32 - $35.99 $3,107 - $3,814
106 Added 192.73%
161 $5,000
Q1 2023

Apr 27, 2023

BUY
$30.15 - $48.79 $1,085 - $1,756
36 Added 189.47%
55 $2,000
Q4 2022

Feb 07, 2023

BUY
$36.73 - $51.6 $697 - $980
19 New
19 $1,000

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.78B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Benjamin Edwards Inc Portfolio

Follow Benjamin Edwards Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Benjamin Edwards Inc, based on Form 13F filings with the SEC.

News

Stay updated on Benjamin Edwards Inc with notifications on news.